Metabolic consequences of the current pharmacologic therapies of women with polycystic ovary syndrome

Jolanta Anna Dardzińska; Dominik Rachoń

Vol 8, No 3 (2012)

Prace poglądowe

Published online: 2012-10-31

View PDF (Polish)

Download PDF file

Get Citation

Metabolic consequences of the current pharmacologic therapies of women with polycystic ovary syndrome

Jolanta Anna Dardzińska, Dominik Rachoń

Endokrynol. Otył. Zab. Przem. Mat 2012;8(3):86-92.

Vol 8, No 3 (2012)

Prace poglądowe

Published online: 2012-10-31

Abstract

Polycystic ovary syndrome (PCOS) is a constellation of various symptoms caused by an excess ovarian androgen production. Menstrual disturbances and clinical signs of hyperandrogenaemia which negatively affect self esteem and quality of life usually begin during adolescence. What is more, at the time of PCOS diagnosis, most women already present with abdominal obesity, carbohydrate and lipid metabolism disturbances and higher, compared to healthy individuals, blood pressure values. Therefore, the diagnosis of PCOS may point to the increased risk of the development of diabetes type 2 and cardiovascular disease which is in accordance with the data from the studies performed in the last ten years. Thus, pharmacotherapy of women with PCOS should not only target clinical signs of hyperandrogenaemia but also consider concomitant metabolic disturbances and additionally to non-pharmacologic treatments, prevent its complications. This review article describes current and novel pharmacologic treatment options of women with PCOS and evaluate their metabolic effects.